Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $138

Benzinga Newsdesk www.benzinga.com Positive 92.5%

Neg 0% Neu 0% Pos 92.5%

Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $138.